ANNX
ANNX clinical trials: Annexon, Inc.
Every trial on ClinicalTrials.gov where Annexon, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 16
- Trials linked
- 16
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ANNX on the catalyst calendar · ANNX registry changes
- Primary completion May 31, 2027Sponsor estimatePhase 3NCT07020819An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome...Annexon, Inc. · Guillain-Barre SyndromeRecruitingANNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2027Sponsor estimatePhase 3NCT06510816A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry...Annexon, Inc. · Geographic AtrophyActive, not recruitingANNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 28, 2023ActualPhase 2NCT04656561A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic AtrophyAnnexon, Inc. · Geographic AtrophyCompletedANNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2029Sponsor estimatePhase 3NCT07807969An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration...Annexon, Inc. · Geographic AtrophyNot yet recruitingANNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 29, 2022ActualPhase 2NCT04514367An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's DiseaseAnnexon, Inc. · Huntington DiseaseCompletedANNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 17, 2023ActualPhase 2NCT04691570Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)Annexon, Inc. · Warm Autoimmune Hemolytic Anemia (wAIHA)CompletedANNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 20, 2024ActualPhase 3NCT04701164Efficacy and Safety of ANX005 in Subjects With Guillain-Barré SyndromeAnnexon, Inc. · Guillain-Barre SyndromeCompletedANNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 10, 2024ActualPhase 2NCT04569435Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)Annexon, Inc. · Amyotrophic Lateral SclerosisCompletedANNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 19, 2024ActualPhase 1NCT05521269Dose Study of ANX1502 in Healthy VolunteersAnnexon, Inc. · HealthyCompletedANNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2023ActualPhase 1NCT05780515A Study of ANX009 in Adult Participants With Lupus NephritisAnnexon, Inc. · Lupus NephritisCompletedANNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 19, 2023ActualPhase 1NCT05288881Single Ascending Dose Study of ANX105Annexon, Inc. · HealthyCompletedANNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 26, 2021ActualPhase 1NCT04535752A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV)Annexon, Inc. · Safety and Tolerability in Healthy VolunteersCompletedANNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 19, 2021ActualPhase 1NCT04035135A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)Annexon, Inc. · Guillain-Barré SyndromeCompletedANNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 3, 2019ActualPhase 1NCT04188015Study of ANX007 in Participants With Primary Open-angle GlaucomaAnnexon, Inc. · Open Angle GlaucomaCompletedANNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 3, 2018ActualPhase 1NCT03488550Single-dose Study of ANX007 in Participants With Primary Open-angle GlaucomaAnnexon, Inc. · Open-angle GlaucomaCompletedANNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2018ActualPhase 1NCT03010046Single Dose Study of ANX005 in Healthy VolunteersAnnexon, Inc. · Safety and Tolerability in Healthy VolunteersTerminatedANNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 16 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner